Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).

Maha HussainClaire CorcoranCaroline SibillaKarim FizaziFred SaadNeal ShoreShahneen SandhuJoaquin MateoDavid OlmosNiven MehraMichael P KolinskyGuilhem RoubaudMustafa ÖzgüroǧluNobuaki MatsubaraCraig GedyeYoung Deuk Choi Charles PaduaAlexander KohlmannRobert HuisdenJulia A ElvinJinyu KangCarrie A AdelmanAllison AllenChristian PoehleinJohann S de Bono

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The PROfound study shows that tissue testing to identify homologous recombination repair alterations is feasible and that high-quality tumor tissue samples are key to obtaining NGS results and identifying patients with mCRPC who may benefit from olaparib treatment.

Keyphrases

phase iii
open label
clinical trial
phase ii
dna repair
dna damage
intellectual disability
small cell lung cancer
double blind
placebo controlled
study protocol
randomized controlled trial
copy number
gene expression
middle aged